The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo
Abstract
BACKGROUND: This report describes the preclinical pharmacological profile of the new rapamycin analog, SDZ RAD, i.e., 40-O-(2-hydroxyethyl)-rapamycin. METHODS: The pharmacological effects of SDZ RAD were assessed in a variety of in vitro and in vivo models, which included an autoimmune disease model as well as kidney and heart allotransplantation models using different rat strain combinations. RESULTS: SDZ RAD has a mode of action that is different from that of cyclosporine or FK506. In contrast to the latter, SDZ RAD inhibits growth factor-driven cell proliferation in general, as demonstrated for the in vitro cell proliferation of a lymphoid cell line and of vascular smooth muscle cells. SDZ RAD is immunosuppressive in vitro as demonstrated by the inhibition of mouse and human mixed lymphocyte reactions and the inhibition of antigen-driven proliferation of human T-cell clones. The concentrations needed to achieve 50% inhibition in all of these assays fall into the subnanomolar range. SDZ RAD is effective in the in vivo models when given by the oral route in doses ranging between 1 mg/kg/day and 5 mg/kg/day. When compared with rapamycin, the in vitro activity of SDZ RAD is generally about two to three times lower; however, when administered orally, SDZ RAD is at least as active in vivo as rapamycin. CONCLUSIONS: In conclusion, SDZ RAD is a new, orally active rapamycin-derivative that is immunosuppressive and that efficiently prevents graft rejection in rat models of allotransplantation. SDZ RAD has therefore been selected for development for use in combination with cyclosporine A to prevent acute and chronic rejection after solid organ allotransplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atomic Structures of the Human Immunophilin FKBP-12 Complexes with FK506 and Rapamycin
Van Duyne, G. D., Standaert, R. F., Karplus, P. A., Schreiber, S. L., & Clardy, J. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1012 · Cited by 1,189
Brahams, D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90821-x · Cited by 533
THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG-TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2
MATAS, A. J., GILLINGHAM, K. J., PAYNE, W. D., & NAJARIAN, J. S. (1994) · Transplantation · doi:10.1097/00007890-199403270-00015 · Cited by 435
RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING
Calne, R. Y., Lim, S., Samaan, A., Collier, D. S. J., Pollard, S. G., White, D. J. G., & Thiru, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90417-0 · Cited by 367
Dumont, F. J., Melino, M. R., Staruch, M. J., Koprak, S. L., Fischer, P. A., & Sigal, N. H. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.4.1418 · Cited by 355
Häyry, P., Isoniemi, H., Yilmaz, S., Mennander, A., Lemström, K., Räisänen‐Sokolowski, A., Koskinen, P., Ustinov, J., Lautenschlager, I., Taskinen, E., et al. (1993) · Immunological Reviews · doi:10.1111/j.1600-065x.1993.tb00639.x · Cited by 290
Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of Action
Sehgal, S. N. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00019 · Cited by 279
Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides
Morris, R. E. (1992) · Transplantation Reviews · doi:10.1016/s0955-470x(10)80014-x · Cited by 253
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Synergism with Cyclosporine
Schuurman, H.-J., Cottens, S., Fuchs, S., Joergensen, J., Meerloo, T., Sedrani, R., Tanner, M., Zenke, G., & Schuler, W. (1997) · Transplantation · doi:10.1097/00007890-199707150-00007 · Cited by 248
Self-citationKOVARIK, J. M., MUELLER, E. A., VAN BREE, J. B., FLÜCKIGER, S. S., LANGE, H., SCHMIDT, B., BOESKEN, W. H., LISON, A. E., & KUTZ, K. (1994) · Transplantation · doi:10.1097/00007890-199409000-00004 · Cited by 242
Cited by
Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Clinical Pharmacokinetics of Everolimus
Kirchner, G. I., Meier-Wiedenbach, I., & Manns, M. P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443020-00002 · Cited by 508
Metadata
- Authors
- Schuler, W., Sedrani, R., Cottens, S., H??berlin, B., Schulz, M., Schuurman, H.-J., Zenke, G., Zerwes, H.-G., & Schreier, M. H.
- Venue
- Transplantation
- Published
- 1997-07
- Volume
- 64
- Issue
- 1
- Pages
- 36-42
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2028549543
- Cited by
- 533
- References
- 22
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo. https://app.cochat.ai/papers/10.1097/00007890-199707150-00008
- The paper
- Schuler, W., Sedrani, R., Cottens, S., H??berlin, B., Schulz, M., Schuurman, H.-J., Zenke, G., Zerwes, H.-G., & Schreier, M. H. (1997). SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo. Transplantation. https://doi.org/10.1097/00007890-199707150-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.